000236598 001 __ 236598
000236598 005 __ 20240926120918.0
000236598 024 7_ $2 doi $a 10.1038/s41408-020-00375-2
000236598 024 8_ $9 scholar $9 driver $9 artpubuab $a oai:ddd.uab.cat:236598
000236598 035 __ $9 scopus_id $a 85094936712
000236598 035 __ $9 articleid $a 20445385v10n11p111
000236598 035 __ $9 pmid $a 33149130
000236598 035 __ $9 pmc-uid $a 7643179
000236598 035 __ $9 pmcid $a PMC7643179
000236598 035 __ $a oai:pubmedcentral.nih.gov:7643179
000236598 041 __ $a eng
000236598 100 1_ $0 0000-0002-5687-6429 $a Kaufman, Jonathan L. $u Emory Winship Cancer Institute
000236598 245 10 $a Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma : $b a cytogenetic subgroup analysis of POLLUX
000236598 251 __ $1 http://purl.org/coar/version/c_970fb48d4fbd8a85 $2 openaire4 $9 VoR $a Versió publicada
000236598 260 __ $c 2020
000236598 520 3_ $a High cytogenetic risk abnormalities confer poor outcomes in multiple myeloma patients. In POLLUX, daratumumab/lenalidomide/dexamethasone (D-Rd) demonstrated significant clinical benefit versus lenalidomide/dexamethasone (Rd) in relapsed/refractory multiple myeloma (RRMM) patients. We report an updated subgroup analysis of POLLUX based on cytogenetic risk. The cytogenetic risk was determined using fluorescence in situ hybridization/karyotyping; patients with high cytogenetic risk had t(4;14), t(14;16), or del17p abnormalities. Minimal residual disease (MRD; 10) was assessed via the clonoSEQ assay V2.0. 569 patients were randomized (D-Rd, n = 286; Rd, n = 283); 35 (12%) patients per group had high cytogenetic risk. After a median follow-up of 44.3 months, D-Rd prolonged progression-free survival (PFS) versus Rd in standard cytogenetic risk (median: not estimable vs 18.6 months; hazard ratio [HR], 0.43; P < 0.0001) and high cytogenetic risk (median: 26.8 vs 8.3 months; HR, 0.34; P = 0.0035) patients. Responses with D-Rd were deep, including higher MRD negativity and sustained MRD-negativity rates versus Rd, regardless of cytogenetic risk. PFS on subsequent line of therapy was improved with D-Rd versus Rd in both cytogenetic risk subgroups. The safety profile of D-Rd by cytogenetic risk was consistent with the overall population. These findings demonstrate the improved efficacy of daratumumab plus standard of care versus standard of care in RRMM, regardless of cytogenetic risk.
000236598 540 __ $9 open access $a Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. $u https://creativecommons.org/licenses/by/4.0/
000236598 546 __ $a Anglès
000236598 599 __ $a recerca
000236598 653 1_ $a Medical research
000236598 653 1_ $a Cancer
000236598 655 _7 $1 http://purl.org/coar/resource_type/c_6501 $2 openaire4 $a Article $c literature
000236598 700 1_ $0 0000-0001-8990-3254 $a Dimopoulos, Meletios $u The National and Kapodistrian University of Athens (Grècia)
000236598 700 1_ $a White, Darrell $u Queen Elizabeth II Health Sciences Centre (Canadà)
000236598 700 1_ $a Benboubker, Lotfi $u Centre Hospitalier Régional Universitaire. Hôpital Bretonneau (França)
000236598 700 1_ $a Cook, Gordon $u St James's Institute of Oncology (Regne Unit)
000236598 700 1_ $a Leiba, Merav $u Assuta Ashdod University Hospital (Israel)
000236598 700 1_ $a Joy Ho, P. $u Royal Prince Alfred Hospital. Institute of Haematology (Austràlia)
000236598 700 1_ $a Kim, Kihyun $u Samsung Medical Center (Corea del Sud)
000236598 700 1_ $a Takezako, Naoki $u National Hospital Organization Disaster Medical Center of Japan
000236598 700 1_ $0 0000-0003-1780-8746 $a Moreau, Philippe $u Hematology. University Hospital Hôtel-Dieu
000236598 700 1_ $a Sutherland, Heather J. $u The University of British Columbia. Leukemia/Bone Marrow Transplant Program
000236598 700 1_ $0 0000-0002-3990-394X $a Magen, Hila $u Tel Aviv University. Department of Hematology Chaim Sheba Medical Center
000236598 700 1_ $a Iida, Shinsuke $u Nagoya City University Graduate School of Medical Sciences
000236598 700 1_ $0 0000-0001-8986-8436 $a Kim, Jin Seok $u Yonsei University. Severance Hospital (Corea del Sud)
000236598 700 1_ $a Miles Prince, H. $u University of Melbourne. Cabrini Hospital (Austràlia)
000236598 700 1_ $a Cochrane, Tara $u Gold Coast University Hospital and Griffiths University (Austràlia)
000236598 700 1_ $0 0000-0001-6804-2221 $a Oriol, Albert $u Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras
000236598 700 1_ $0 0000-0001-7353-7034 $a Bahlis, Nizar J. $u University of Calgary. Arnie Charbonneau Cancer Institute (Canadà)
000236598 700 1_ $0 0000-0002-0405-7480 $a Chari, Ajai $u Icahn School of Medicine at Mount Sinai (Nova York, Estats Units d'Amèrica)
000236598 700 1_ $a O'Rourke, Lisa $u Janssen Research & Development (Estats Units d'Amèrica)
000236598 700 1_ $a Trivedi, Sonali $u Janssen Research & Development (Estats Units d'Amèrica)
000236598 700 1_ $a Casneuf, Tineke $u Janssen Research & Development (Estats Units d'Amèrica)
000236598 700 1_ $a Krevvata, Maria $u Janssen Research & Development (Estats Units d'Amèrica)
000236598 700 1_ $a Ukropec, Jon $u Janssen Global Medical Affairs (Estats Units d'Amèrica)
000236598 700 1_ $a Kobos, Rachel $u Janssen Research & Development (Estats Units d'Amèrica)
000236598 700 1_ $a Avet-Loiseau, Hervé $u Unite de Genomique du Myelome. IUC-Oncopole (França)
000236598 700 1_ $0 0000-0002-5484-8731 $a Usmani, Saad $u Levine Cancer Institute/Atrium Health (Estats Units d'Amèrica)
000236598 700 1_ $0 0000-0002-9183-4857 $a San-Miguel, J. $u Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada
000236598 710 2_ $9 500 $a Universitat Autònoma de Barcelona
000236598 773 __ $g Vol. 10 Núm. 11 (january 2020), p. 111 $t Blood Cancer Journal $x 2044-5385
000236598 856 40 $p 10 $s 683678 $u https://ddd.uab.cat/pub/artpub/2020/236598/236598.pdf
000236598 973 __ $f 0111 $m 1 $n 11 $v 10 $x 2044-5385_a2020v10n11 $y 2020
000236598 980 __ $a ARTPUB $b UAB $b IGTPCONV